Navigation Links
S*BIO Initiates Phase 2 Clinical Trial of its Novel JAK2 Inhibitor SB1518 in North America for Advanced Lymphoid Malignancies
Date:4/14/2011

SINGAPORE, April 14, 2011 /PRNewswire/ -- S*BIO Pte Ltd today announced that it has dosed the first 10 patients in a Phase 2 clinical trial of its novel JAK2 inhibitor SB1518 in the U.S. and Canada for the treatment of advanced lymphoid malignancies.

This multi-center, open-label, study is designed to primarily evaluate the efficacy and safety of SB1518 in patients with advanced lymphoid malignancies in five sites including M.D. Anderson, Rochester University, Cornell University, University of Nebraska, and British Columbia Cancer Center. Secondary objectives include duration of response and progression-free survival.  Based on the safety and clinical benefit data from a Phase 1 trial, patients are receiving a 400mg dose of SB1518 orally daily. The trial will enroll up to 87 lymphoma patients and will determine the efficacy of SB1518 in the treatment of patients with advanced lymphoid malignancies such as Hodgkin's Lymphoma, Mantle Cell Lymphoma and Indolent Lymphoma.

Previously presented lymphoma data at the 52nd ASH Annual Meeting and Exposition demonstrated SB1518's clinical benefits in a Phase 1 dose ranging study. Three patients showed partial response and 15 patients maintained stable disease states.  The majority of the responses were sustained for greater than two months.

"The development of SB1518 in a second indication is a significant milestone in the clinical advancement of our lead JAK2 inhibitor," said Dr. Jan-Anders Karlsson, CEO of S*BIO. "The initiation of this Phase 2 trial demonstrates our commitment in advancing this best-in-class compound and addressing the unmet medical need for an effective treatment of lymphoma.  This trial closely follows our recent announcement of data from Phase 1/2 studies for SB1518 indicating its clinical efficacy and good tolerability for the treatment of patients with symptomatic myelofibrosis and enlarged spleens."

S*BIO Pte Ltd and Onyx Pharmaceuticals, Inc. have a dev
'/>"/>

SOURCE S*BIO Pte Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. S*BIO Completes US$26 Million Equity Financing
2. S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317
3. S*BIO Receives BioSpectrum Editors Choice, Emerging BioScience Company of Singapore Award
4. S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders
5. S*BIO and Onyx Pharmaceuticals Announce Expanded Development Collaboration for JAK2 Inhibitors
6. S*BIO Announces US$5 Million Investment by Mitsui Ventures
7. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
8. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
9. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
10. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
11. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... 2014 Called the NOAH Protocol, ... several types of pediatric brain cancer. The implications ... over 30 years of research and development. Amber ... that one mom's determination can make a difference. ... trick-or-treating, and it’s only fitting that we’ve received ...
(Date:10/27/2014)... , Oct. 27, 2014 Pressure ... a worldwide leader in the development and sale ... life sciences research market, today announced that Professor ... a novel, accurate, highly reproducible, and robust method ... routine high-throughput protein analysis on small needle biopsy ...
(Date:10/27/2014)... Investor-Edge has initiated coverage on ... NBIX ), Insmed Inc. (NASDAQ: INSM ), ... Corporation (NASDAQ: DYAX ), and Oncothyreon Inc. ... be accessed at: http://investor-edge.com/register . On ... 4,483.72, up 0.69%, the Dow Jones Industrial Average advanced ...
(Date:10/26/2014)... The report "Protective Coatings Market by Resin Type, by ... to 2019", defines and segments the global protective coatings ... value generated. The protective coatings consumption is projected to ... by 2019, at a CAGR of 9.52% during the ... 22 figures spread through 219 slides and in-depth TOC ...
Breaking Biology Technology:FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 2FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 3Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 2Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 3Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 4Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 5Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 2Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 5Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 2Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 3Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 4
... February 5, SAN DIEGO, Jan. 24 Neurocrine ... Company will report its fourth,quarter and year-end 2007 financial ... 2008. Neurocrine will then host a live conference,call and ... Company,update Tuesday afternoon, February 5, 2008 at 5:00 p.m. ...
... Jan. 24 Biomatrica, the biostability company,that offers ... has introduced RNAstable(TM) for preserving RNA at room,temperature, ... Interest in RNA has skyrocketed over the ... silencer and in gene expression studies. However, RNA ...
... Jan. 24 Aton Pharma, Inc., ... that it has,launched an expanded, comprehensive ... and patient education resources, for the,dry ... Lacrisert is a unique preservative-free, once-daily*, ...
Cached Biology Technology:Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results 2Biomatrica's RNAstable(TM) Stabilizes RNA at Room Temperature 2Biomatrica's RNAstable(TM) Stabilizes RNA at Room Temperature 3Aton Pharma Introduces Expanded Distribution of Lacrisert(R) (hydroxypropyl cellulose ophthalmic insert) at Hawaiian Eye 2Aton Pharma Introduces Expanded Distribution of Lacrisert(R) (hydroxypropyl cellulose ophthalmic insert) at Hawaiian Eye 3
(Date:10/29/2014)... research by the international Cancer Genomics of the ... connection between kidney cancer and exposure to aristolochic ... findings, published in Nature Communications , have ... kills more than 140,000 people every year, and ... dramatically. CAGEKID, part of the International Cancer Genome ...
(Date:10/28/2014)... the tragic realities of cancer is that the ... and their effectiveness varies unpredictably from patient to ... to change this reality by rapidly assessing how ... individual,s cancer before chemotherapy begins. , A team ... Assistant Professor Melissa Skala has developed the technique, ...
(Date:10/28/2014)... from North America, Europe and China have published a ... of Sciences that reveals important details about key ... planet., From strange and exotic algae, mosses, ferns, trees ... grains and vegetables we eat and the ornamental plants ... over a billion years of history., "Our study generated ...
Breaking Biology News(10 mins):Kidney cancer in Central Europe 2Improving breast cancer chemo by testing patient's tumors in a dish 2Improving breast cancer chemo by testing patient's tumors in a dish 3New study uses DNA sequences to look back in time at key events in plant evolution 2New study uses DNA sequences to look back in time at key events in plant evolution 3
... An entire group of millipedes previously unknown in ... shelves. Hundreds of tiny specimens of the widespread tropical family ... showing that native pyrgodesmids are not only widespread ... and diverse. The study has been published in the open ...
... 2012For many diabetics, monitoring their condition involves much more ... insulin injections. It also entails carefully monitoring the ongoing ... An innovative new optical diagnostic tool created by Columbia ... (OSA) open-access journal Biomedical Optics Express may ...
... of Leicester medical scientists have secured funding for a ... into children,s breathing. The team of researchers working ... Exhalyzer-D, a highly-specialised device made in Switzerland. ... grants from Midlands Asthma and Allergy Research Association (MAARA) ...
Cached Biology News:Millipede family added to Australian fauna 2Shedding new light on one of diabetes' most dangerous complications 2New equipment is breath of fresh air for children's lung researchers 2